Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Nutcracker Therapeutics Inc. is active in the Biotechnology & Pharmaceuticals technology area with 1 pending office action. This prosecution activity is handled by 1 distinct examiner and 1 distinct art unit, indicating a singular focus for the company's current patent office engagements. The narrow distribution suggests that the company's current legal efforts are directed toward a single specific application. Practitioners should note that the involvement of 1 distinct art unit simplifies the administrative tracking of the application.
The busiest examiner for this portfolio is DENT, ALANA HARRIS, who manages 1 busiest examiner pending office action. This count matches the total of 1 pending office action for the entire portfolio, showing that this examiner is responsible for all active legal proceedings. Because there is only 1 distinct examiner, the prosecution environment is highly centralized for the applicant. Practitioners should note that the 1 busiest examiner pending office action represents the total active workload, requiring focused attention on this single individual's review process to ensure the company's patent goals are met.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DENT, ALANA HARRIS | 1 | 44.2% | +32.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17998574 | POLYNUCLEOTIDES COMPRISING AN ANTIGENIC PAYLOAD | DENT, ALANA HARRIS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17998574 | POLYNUCLEOTIDES COMPRISING AN ANTIGENIC PAYLOAD | DENT, ALANA HARRIS | — |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17998574 | POLYNUCLEOTIDES COMPRISING AN ANTIGENIC PAYLOAD | DENT, ALANA HARRIS | 1643 | §102§103§112 | Non-Final OA | — | Pending | Nov 11, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial